Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Post-transplant lymphoproliferative disorder

Post-transplant lymphoproliferative disorder

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Post-transplant lymphoproliferative disorder

11 trials tracked for Post-transplant lymphoproliferative disorder.

11Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 10 Other / NA 1
  1. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  2. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  3. Phase 2 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed
  4. Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed
  5. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  6. Phase 2 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Completed
Show 5 more trials
  1. Phase 2 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Completed
  2. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  3. Phase 2 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  4. Phase 2 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  5. N/A Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
EBV-driven mechanisms in kidney transplant recipients reshape the tumor microenvironment in post-transplant lymphoproliferative disorder
Oncology Sys. Review
EBV-driven mechanisms in kidney transplant recipients reshape the tumor microenvironment in post-transplant lymphoproliferative disorder Is your transplant rejection risk higher than you think when fighting this specific cancer?
This systematic review examines mechanisms by which Epstein-Barr Virus remodels the cellular landscape in post-transplant lymphoproliferativ…
Kidney cancer driven by Epstein-Barr virus now uses a fortress-like shield to hide, forcing doctors to choose between saving the organ or fi…
Frontiers Apr 9, 2026